Luteolin Inhibits Lung Metastasis, Cell Migration, and Viability of Triple-negative Breast Cancer Cells

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2017 Jan 19

PMID 28096694

Citations 34

Authors

Matthew T Cook

Yayun Liang

Cynthia Besch-Williford

Salman M Hyder

Affiliations

Soon will be listed here.

Abstract

Most breast cancer-related deaths from triple-negative breast cancer (TNBC) occur following metastasis of cancer cells and development of tumors at secondary sites. Because TNBCs lack the three receptors targeted by current chemotherapeutic regimens, they are typically treated with extremely aggressive and highly toxic non-targeted treatment strategies. Women with TNBC frequently develop metastatic lesions originating from drug-resistant residual cells and have poor prognosis. For this reason, novel therapeutic strategies that are safer and more effective are sought. Luteolin (LU) is a naturally occurring, non-toxic plant compound that has proven effective against several types of cancer. With this in mind, we conducted in vivo and in vitro studies to determine whether LU might suppress metastasis of TNBC. In an in vivo mouse metastasis model, LU suppressed metastasis of human MDA-MB-435 and MDA-MB-231 (4175) LM2 TNBC cells to the lungs. In in vitro assays, LU inhibited cell migration and viability of MDA-MB-435 and MDA-MB-231 (4175) LM2 cells. Further, LU induced apoptosis in MDA-MB-231 (4175) LM2 cells. Relatively low levels (10 µM) of LU significantly inhibited vascular endothelial growth factor (VEGF) secretion in MDA-MB-231 (4175) LM2 cells, suggesting that it has the ability to suppress a potent angiogenic and cell survival factor. In addition, migration of MDA-MB-231 (4175) LM2 cells was inhibited upon exposure to an antibody against the VEGF receptor, KDR, but not by exposure to a VEGF antibody. Collectively, these data suggest that the anti-metastatic properties of LU may, in part, be due to its ability to block VEGF production and KDR-mediated activity, thereby inhibiting tumor cell migration. These studies suggest that LU deserves further investigation as a potential treatment option for women with TNBC.

Citing Articles

Role of flavonoids in inhibiting triple-negative breast cancer.

Wang S, Wang K, Li C, Chen J, Kong X Front Pharmacol. 2024; 15:1411059.

PMID: 39257397 PMC: 11384598. DOI: 10.3389/fphar.2024.1411059.

Co-administration of Chrysin and Luteolin with Cisplatin and Topotecan Exhibits a Variable Therapeutic Value in Human Cancer Cells, HeLa.

Raina R, Hussain A, Almutary A, Haque S, Raza T, DSouza A ACS Omega. 2023; 8(44):41204-41213.

PMID: 37970041 PMC: 10633856. DOI: 10.1021/acsomega.3c04443.

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review.

Fakhri S, Moradi S, Faraji F, Kooshki L, Webber K, Bishayee A Cancer Metastasis Rev. 2023; 43(1):501-574.

PMID: 37792223 DOI: 10.1007/s10555-023-10136-9.

Molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer based on network pharmacology.

Chu M, Meng T, Zhou Y, Jin L, Dai Q, Ma L Medicine (Baltimore). 2023; 102(35):e34763.

PMID: 37657065 PMC: 10476815. DOI: 10.1097/MD.0000000000034763.

Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling.

Wu L, Lin Y, Gao S, Wang Y, Pan H, Wang Z Front Pharmacol. 2023; 14:1200843.

PMID: 37346292 PMC: 10279868. DOI: 10.3389/fphar.2023.1200843.

References

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Gasparini G . Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000; 5 Suppl 1:37-44. DOI: 10.1634/theoncologist.5-suppl_1-37. View

Chiu F, Lin J . Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate. 2007; 68(1):61-71. DOI: 10.1002/pros.20690. View

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

Kim H, Jung S, Byun S, Son J, Oh M, Lee J . Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin. Phytother Res. 2012; 27(10):1481-8. DOI: 10.1002/ptr.4888. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Price J . Metastasis from human breast cancer cell lines. Breast Cancer Res Treat. 1996; 39(1):93-102. DOI: 10.1007/BF01806081. View

Liang Y, Hyder S . Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology. 2005; 146(8):3632-41. DOI: 10.1210/en.2005-0103. View

10.

Lund M, Butler E, Hair B, Ward K, Andrews J, Oprea-Ilies G . Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010; 116(11):2549-59. DOI: 10.1002/cncr.25016. View

11.

Price D, Miralem T, Jiang S, Steinberg R, Avraham H . Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001; 12(3):129-35. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View

14.

Arvold N, Taghian A, Niemierko A, Abi Raad R, Sreedhara M, Nguyen P . Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29(29):3885-91. PMC: 3189090. DOI: 10.1200/JCO.2011.36.1105. View

15.

Zhou Q, Yan B, Hu X, Li X, Zhang J, Fang J . Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 2009; 8(6):1684-91. DOI: 10.1158/1535-7163.MCT-09-0191. View

16.

Ricardo S, Vieira A, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro J . Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011; 64(11):937-46. DOI: 10.1136/jcp.2011.090456. View

17.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

18.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

19.

Lee E, Oh S, Sung M . Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol. 2012; 50(11):4136-43. DOI: 10.1016/j.fct.2012.08.025. View

20.

Pratheeshkumar P, Son Y, Budhraja A, Wang X, Ding S, Wang L . Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One. 2013; 7(12):e52279. PMC: 3534088. DOI: 10.1371/journal.pone.0052279. View